Successful mycophenolate mofetil treatment of glomerular disease

William A. Briggs, Michael J. Choi, Paul J. Scheel

Research output: Contribution to journalArticlepeer-review

182 Scopus citations


Eight patients with resistant and/or relapsing nephrotic syndrome or renal insufficiency were empirically treated with mycophenolate mofetil (MMF). The underlying glomerular diseases were membranous nephropathy (N = 3), minimal change disease (n = 2), focal segmental glomerulosclerosis (n = 1), and lupus nephritis (N = 2). Treatment with MMF 0.75 to 1.0 g twice daily, either as monotherapy or in combination with low-doses steroid treatment, resulted in substantial reductions in proteinuria or stabilization of serum creatinine. In relapsing patients following withdrawal from cyclosporin A, MMF achieved suppression of proteinuria equivalent to or better than that which occurred during cyclosporin A treatment. Steroids were successfully withdrawn in each of the non-lupus patients. MMF was well tolerated with no evidence of hematologic, hepatic, or other toxicity. These clinical anecdotes demonstrate the short-term clinical efficacy of MMF treatment. In addition, they suggest that MMF may have major steroid-sparing effects and might represent an alternative to cyclosporin A in appropriate patients.

Original languageEnglish (US)
Pages (from-to)213-217+364-365
JournalAmerican Journal of Kidney Diseases
Issue number2
StatePublished - Feb 1998
Externally publishedYes


  • Glomerular disease
  • Mycophenolate mofetil
  • Nephrotic syndrome

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Successful mycophenolate mofetil treatment of glomerular disease'. Together they form a unique fingerprint.

Cite this